Table 1 Characteristics of patients and treatments
All patients | |
|---|---|
N = 180 | |
Age (median [range]) years | 70.5 [49.6–84.9] |
T stage-n (%) | |
T1c | 57 (31.7 %) |
T2a | 31 (17.2 %) |
T2b | 37 (20.6 %) |
T2c | 19 (10.6 %) |
T3a | 30 (16.7 %) |
T3b | 6 (3.3 %) |
PSA (ng/ml) (median [range]) | 10 [0.8–99] |
Gleason score-n (%) | |
≤ 6 | 103 (57.2 %) |
7 | 64 (35.6 %) |
≥ 8 | 13 (7.2 %) |
Risk groups-n (%) | |
Low risk | 48 (26.7 %) |
Intermediate risk | 68 (37.8 %) |
High risk | 64 (35.6 %) |
Hormone therapy-n (%) | |
Neoadjuvant | 50 (27.8 %) |
Concomitant | 69 (38.3 %) |
Adjuvant | 70 (38.9 %) |
Radiotherapy: prostate dose (2Gy/fxa) | 78 [70–80] |
Median [range] | |
TURPb-n (%) | |
Yes | 35 (19.7 %) |
No | 143 (80.3 %) |
Missing | 2 (1.1 %) |